ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO417

Incidences of ESKD and Death Before ESKD Among US Veterans with New-Onset CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Yan, Guofen, University of Virginia, Charlottesville, Virginia, United States
  • Greene, Tom, University of Utah, Salt Lake City, Utah, United States
  • Nee, Robert, Walter Reed National Military Medical Center, Vienna, Virginia, United States
  • Cheung, Alfred K., University of Utah, Salt Lake City, Utah, United States
  • Oliver, Mohammed Norman, Virginia Department of Health, Richmond, Virginia, United States
  • Yu, Wei, University of Virginia, Charlottesville, Virginia, United States
  • Norris, Keith C., UCLA, Marina Del Rey, California, United States
Background

Epidemiologic data on competing-risk events of progressing to ESKD or dying before ESKD are mixed due to prevalent cohorts used. Using a recently constructed national incident CKD cohort, we report the 5-year incidence of these two events following new CKD onset by demographics, kidney function and comorbid conditions.

Methods

The cohort included 534,972 subjects with new onset CKD (stage 3-5) between 2002 and 2011 in the U.S. Veteran Affairs database. CKD onset was determined by two eGFRs (based on CKD-EPI equation) <60 mL/min/1.73 m2 at >90 days apart. We excluded subjects in the database who had <2 years before the first eGFR<60 or had prior ESKD. As such, the index date identified was very close to new onset CKD. All subjects were followed for 5 years.

Results

The three groups had similar mean eGFRs at onset (range 49-50 ml/min/1.73m2) and gender distributions (97-98% male). Blacks had younger onset age (mean 67 yrs) than Hispanics (71 yrs) and whites (74 yrs). Over the course of 5 years after onset, approximately two-thirds of the initial cohort remained alive in pre-ESKD, with Blacks having a lower percentage (65%) than Hispanics and Whites (68%). Among the one-third who progressed, Blacks and Hispanics had greater percentages who progressed to ESKD than Whites (10%, 7%, and 2%, respectively), whereas they had smaller percentages of dying before ESKD (25%) than Whites (30%). Males were more likely than females to develop these two events. The relative likelihood of the two events also varied by age and eGFR stage (Table), as well as comorbidities such as diabetic and hypertensive status and cardiovascular diseases (not shown).

Conclusion

Improving outcomes for patients with CKD could be more effective by identifying risk factors associated with differential risks of developing ESKD and dying before ESKD.

Percentages of events within 5 years of CKD onset
 Black (n=56,949)Hispanic (n=17,414)White (n=460,609)
GroupAlive in pre-ESKD ESKDDeath before ESKDAlive in pre-ESKD ESKDDeath before ESKDAlive in pre-ESKD ESKDDeath before ESKD
Overall65.110.224.767.76.725.668.12.329.6
Male64.810.225.067.56.825.867.92.329.8
Female77.99.312.881.54.414.077.51.221.3
Age 18-5561.925.013.162.523.713.875.19.315.6
Age 56-7570.39.320.473.27.419.475.93.021.1
Age >7555.12.442.560.41.737.960.21.138.7
eGFR 30-5968.07.424.669.94.825.369.41.529.1
eGFR <3023.851.125.128.940.430.734.922.143.1

Funding

  • NIDDK Support